NCT02035358 - Immunotherapy Study for Metastatic Renal Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

January 3, 2017

Study Completion Date

January 12, 2021

Conditions

Metastatic Renal Cell CarcinomaMetastatic Clear-cell Renal CancerRecurrent Renal Cell CarcinomaRefractory Renal Cell CarcinomaMetastatic Kidney Cancer

Interventions

BIOLOGICAL

HyperAcute®-Renal (HAR) Immunotherapy

"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."

Trial Locations (3)

21205

John Hopkins University, Baltimore

52242

University of Iowa Hospitals and Clinics, Iowa City

84112

Univeristy of Utah, Salt Lake City